Abstract: The present technology generally relates to compounds, in particular peptides comprising the heparin-binding domain (HBD) of insulin-like growth factor binding protein-2 (IGFBP-2) for the modulation of metabolic disorders. The present technology also generally relates to uses of such compounds in methods for preventing and/or treating metabolic disorders and in compositions and formulations for such uses.

Abstract: The present technology generally relates to compounds, in particular peptides comprising the heparin-binding domain (HBD) of insulin-like growth factor binding protein-2 (IGFBP-2) for the modulation of metabolic disorders. The present technology also generally relates to uses of such compounds in methods for preventing and/or treating metabolic disorders and in compositions and formulations for such uses.

Abstract: The present technology generally relates to compounds, in particular peptides comprising the heparin-binding domain (HBD) of insulin-like growth factor binding protein-2 (IGFBP-2) for the modulation of metabolic disorders. The present technology also generally relates to uses of such compounds in methods for preventing and/or treating metabolic disorders and in compositions and formulations for such uses.

Abstract: The invention describes novel PAR polypeptides and uses thereof. It relates in particular to PAR polypeptides lacking their functional endogenous activating peptide and capable of interacting constitutively with a ligand for a wild-type PAR. The invention also lies in methods of screening for active compounds, using modified PAR polypeptides, and also in the therapeutic use of identified compounds, in particular for the treatment of inflammation, of allergies, of diseases affecting the CNS, of neurodegeneration, or of psychiatric or cardiovascular diseases, and also in methods and compositions which can be used for this purpose. Other subjects of the invention include nucleic acids encoding a modified PAR, vectors and recombinant host cells and transgenic animals containing them, and also their uses in the context of a therapeutic, diagnostic or screening approach, for example.

Abstract: The invention relates to a method for treating a functional dyspepsia by administering to a mammal in need thereof a preparation comprising a recombinant gastric lipase. The invention also relates to pharmaceutical compositions comprising a recombinant gastric lipase and methods of use.